[Implementation of GEC-ESTRO recommendations on 3-D based image brachytherapy]

Area of Science:

• Oncology
• Radiation Oncology
• Medical Imaging

Background:

• Concomitant chemoradiation has improved cervical cancer prognosis.
• Brachytherapy remains essential for treating FIGO stages I-IV cervical carcinoma.
• Advancements in 3D imaging and dosimetry enhance understanding of treatment targets and organs at risk.

Purpose of the Study:

• To review the role and advancements in 3D image-guided brachytherapy for cervical cancer.
• To discuss the GEC-ESTRO recommendations for defining volumes of interest in brachytherapy.
• To analyze dose-volume histogram data for normal tissues and tumor targets.

Main Methods:

• Review of 2005 and 2006 GEC-ESTRO recommendations for 3D image-based brachytherapy.
• Validation of recommendations through intercomparison delineation studies.
• Analysis of dose-volume histograms (DVH) for assessing dose to normal tissues.

Main Results:

• Established dose limits for the bladder (90 Gy to 2 cm³) and rectum (similar to ICRU point for 2 cm³).
• The sigmoid colon is under further study due to limited prior research.
• Dose to the high-risk clinical target volume (HR-CTV) or intermediate-risk CTV (IR-CTV) requires further clarification, likely dependent on tumor extent.

Conclusions:

• 3D image-guided brachytherapy has significantly improved target and organ-at-risk delineation in cervical cancer treatment.
• GEC-ESTRO recommendations provide a framework for defining volumes of interest and analyzing dose-volume data.
• Further research is needed to optimize dose prescription for tumor targets and understand dose constraints for organs like the sigmoid.